About

Podcasts

Discussing Rheumatology: October 2023

Podcasts

EULAR Recommendations Podcast 2023 with Professor Peter Nash & Dr. Andreas Kerschbaumer

Podcasts

Author Interview: Professor Martin Bergman, 2023

Publications

Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis

Publications

Risk of Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic, Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drugs: Observational Data from the German RABBIT Register

Publications

Therapy with JAK Inhibitors or bDMARDs and the Risk of Cardiovascular Events in the Dutch Rheumatoid Arthritis Population

Publications

Bimekizumab Treatment in Patients With Active Axial Spondyloarthritis: 52-week Efficacy and Safety from the Randomised Parallel Phase 3 BE MOBILE 1 and BE MOBILE 2 Studies

Publications

Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data

Publications

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib

Podcasts

Upadacitinib treating bDMARD-IR PsA & Post-marketing surveillance of tofacitinib treating PsA & RA

Publications

Global, Regional, and National Burden of Rheumatoid Arthritis, 1990–2020, and Projections to 2050: a Systematic Analysis of the Global Burden of Disease Study 2021

Publications

Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis

Podcasts

Discussing Rheumatology: September 2023

Podcasts

AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab

Publications

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Publications

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study

Publications

Anti-GM-CSF Otilimab Versus Tofacitinib or Placebo in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Conventional or Biologic DMARDs: Two Phase 3 Randomised Trials (contRAst 1 and contRAst 2)

Publications

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice

Publications

Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from the Phase III, Randomised, Placebo-Controlled, Active Reference BE OPTIMAL Study

Publications

Anti-gm-csf Otilimab versus Sarilumab or Placebo in Patients with Rheumatoid Arthritis and Inadequate Response to Targeted Therapies: A Phase III Randomised Trial (contRAst 3)

Publications

Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data

Publications

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials

Publications

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses

Publications

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients with Active Ankylosing Spondylitis

Publications

A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis

Publications

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT Phase 3b trial

Publications

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

Podcasts

Author Interview: Sofia Ramiro

Publications

Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-mediated Inflammatory Diseases

Publications

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

Podcasts

Discussing Rheumatology: August 2023

Publications

Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis: Analysis of Pooled Data from Two Phase 3 Studies